Navigation Links
Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
Date:6/1/2009

e chemotherapy treatment.

"We are pleased that the PIX 301 EXTEND trial of pixantrone demonstrated a long-lasting clinical benefit in this heavily pretreated relapsed/refractory group of patients with aggressive NHL and look forward to completing the New Drug Application submission later this month," said James A. Bianco, M.D., Chief Executive Officer of CTI. "Given the lack of approved therapies for this resistant group of patients with aggressive NHL, we believe pixantrone offers a valuable therapy for this unmet medical need."

The most common grade 3, 4 adverse event observed on the pixantrone arm was neutropenia in 41.2% of patients versus 19.4% on the comparator arm. However, the incidence of grade 3, 4 febrile neutropenia was only 7.4% versus 3.0% in the comparator arm. Grade 3, 4 infections had a similar incidence in both study arms (18% vs. 13%). Although the grade 3, 4 cardiac disorder was similar among the two treatment groups (1.5% vs. 1.5%), there was a slightly higher incidence of serious cardiac disorders in patients treated with pixantrone than among patients who received comparator agents (8.8% vs. 4.5%). Events considered cardiac disorders included cardiac arrest, congestive heart failure, myocardial infarction, cyanosis, pericardial effusion, and tachycardia.

The ASCO poster is available at http://www.celltherapeutics.com/investor_updates.

In April 2009, CTI began a rolling submission of a New Drug Application ("NDA") with the U.S. Food and Drug Administration (the "FDA") for pixantrone to treat relapsed or refractory aggressive NHL. CTI expects to complete the submission this month and will request priority review which if granted could lead to an approval decision from the FDA in the fourth quarter of 2009.

'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Discussions With FDA on Pixantrone EXTEND (PIX301) Trial Provide Path for NDA Submission
2. Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
3. Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial
4. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
5. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
6. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
7. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
8. New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
9. Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
10. Cord Blood America CEO Matthew Schissler Says Operations Significantly Streamlined
11. Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)...  Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the ... of high pressure-based sample preparation systems to the life ... to present at the 2 nd  Global Life ... The Conference will take place at the Warsaw Stock ... Schumacher , President and CEO of PBI, will present ...
(Date:10/1/2014)... City, CA (PRWEB) October 01, 2014 As ... it leaves no room for doubt that this century would ... innovations in the field of medicine science. The fact that ... problems is not unknown to the scientific community. Almost half ... pollution and therefore can be prevented with medical care and ...
(Date:10/1/2014)... 2014 New applications of structures and ... evolved in nature over millennia are featured in a ... for applications in biophotonics in the October issue of ... is published by SPIE, the international society for optics ... the peer-reviewed articles are accessible via open access. , ...
(Date:10/1/2014)... 01, 2014 The U.S. Department of ... Illinois University Edwardsville as part of the Trade Adjustment ... funding is co-administered by the Department of Labor and ... of Labor Thomas E. Perez and Secretary of Education ... job-driven training grants to nearly 270 colleges across the ...
Breaking Biology Technology:Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 2Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 3Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 4Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 2Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 3Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 3U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 4
... WASHINGTON, Oct. 5 The Coalition for a,Competitive ... the Food and Drug Administration,s announcement regarding its,"Generic ... consumers, employers, insurers, and policymakers grappling with,how to ... that FDA,and Congress continue to focus on ways ...
... Lexicon,Pharmaceuticals, Inc. (Nasdaq: LXRX ) today announced that ... officer, will present,at the BIO InvestorForum at The Palace ... at 11:00 a.m. Pacific Time. A live webcast ... at http://www.lexpharma.com . An archived version of the,webcast ...
... Pharmasset, Inc.,(Nasdaq: VRUS ) has entered into ... Subject to certain terms and conditions of,the agreement, Horizon ... At its option, Pharmasset may receive a second loan ... loan of $10 million by November 30, 2008,provided conditions ...
Cached Biology Technology:CCPM Issues Statement on FDA's GIVE Initiative 2Lexicon Pharmaceuticals to Present at Bio InvestorForum 2Pharmasset Accesses up to $30 Million of Working Capital 2Pharmasset Accesses up to $30 Million of Working Capital 3
(Date:9/30/2014)... (PCE) in drinking water may increase the risk ... new study led by a Boston University School ... in the journal Environmental Health , compared ... 1,766 women in Cape Cod, Ma., where water ... early 1980s by the installation of vinyl-lined asbestos ...
(Date:9/30/2014)... FRANKFURT. Truffles, along ... world. Because they grow underground, people use trained dogs or ... is not only of interest to gourmets. A group of ... University Frankfurt have discovered that the smell of white truffles ... truffle fruiting bodies. , White truffles from the Piedmont region ...
(Date:9/30/2014)... Researchers of Ludwig-Maximilians-Universitaet (LMU) in Munich report that ... cells more sensitive to chemotherapeutic drugs. They have ... a new target for anti-tumor agents. , ... Professor Stephan Sieber of the Technische Universitt Mnchen ... a potential new weapon in the fight against ...
Breaking Biology News(10 mins):Contaminated water linked to pregnancy complications, BU study finds 2On the trail of the truffle flavor 2Cancer therapy: Driving cancer cells to suicide 2
... minds about the head size of an ancient human ancestor, ... may have been. Found in Gona, Ethiopia, not far from ... of the famed Australopithecus afarensi "Lucy," the pelvis indicates that ... ago, had a larger birth canal than originally suspected and ...
... , 2008 Arbor Vita Corporation (AVC), a ... its rapid, point-of-care prototype HPV test with a high ... for use throughout the developing world, this diagnostic test ... presentation, "Development of a Rapid Diagnostic Test for Cervical ...
... to make cancer treatment safer A new piece ... (NPL) today will help improve the success rates of ... (linac) will help ensure patients are treated with accurate ... using ionising radiation such as high-energy X-rays or electron ...
Cached Biology News:Arbor Vita presents new data on cancer diagnostic at EUrogin 2NPL unveils new equipment to make cancer treatment safer 2
Required to perform reference file generation, flatfield calibration and performance verification processes on the GSD-501...
ssDNA from PCR DNA in less than 1 hour. No gels, columns, or slurries. Sequence from high quality ssDNA: clearer reads, longer runs....
... of Freezerworks Unlimited includes 2 clients and streamlines ... the sharing of freezers by multiple groups without ... Network Client/Server version for ... monitor with 256 colors; OS 8.6 & OS ...
Applications: Immunohistochemistry, ISH, FISH, CISH....
Biology Products: